UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

Journal of cystic fibrosis, 2016-11, Vol.15 (6), p.783-790

2016

Volltextzugriff (PDF)

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Journal of cystic fibrosis, 2017-09, Vol.16 (5), p.607-615

2017

Volltextzugriff (PDF)

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study

Journal of cystic fibrosis, 2015-09, Vol.14 (5), p.632-638

2015

Volltextzugriff (PDF)

Adults with cystic fibrosis in Portugal: A first step towards improvement

Revista portuguesa de pneumologia (English ed.), 2016-05, Vol.22 (3), p.139-140

2016

Volltextzugriff (PDF)

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

The Lancet (British edition), 2018-09, Vol.392 (10150), p.880-890

2018

Volltextzugriff (PDF)

EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin

Journal of cystic fibrosis, 2017-06, Vol.16, p.S54-S54

2017

Volltextzugriff (PDF)

Corrigendum to “Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study” [J Cyst Fibros (2015) 632–638]

Journal of cystic fibrosis, 2016-09, Vol.15 (5), p.e54-e55

2016

Volltextzugriff (PDF)

WS7.5 Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic Pseudomonas aeruginosa infection

Journal of cystic fibrosis, 2014-06, Vol.13, p.S16-S16

2014

Volltextzugriff (PDF)

WS13.2 Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects

Journal of cystic fibrosis, 2017-06, Vol.16, p.S23-S23

2017

Volltextzugriff (PDF)

WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics

Journal of cystic fibrosis, 2014-06, Vol.13, p.S6-S6

2014

Volltextzugriff (PDF)

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

The New England journal of medicine, 2015-07, Vol.373 (3), p.220-231

2015

Volltextzugriff (PDF)

A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis

Value in health, 2014-11, Vol.17 (7), p.A551-A551

2014

Volltextzugriff (PDF)

WS23.6 Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study

Journal of cystic fibrosis, 2014-06, Vol.13, p.S44-S44

2014

Volltextzugriff (PDF)

321 Timing of inhaled tobramycin affects intravenous tobramycin trough levels

Journal of cystic fibrosis, 2011, Vol.10, p.S82-S82

2011

Volltextzugriff (PDF)

82 Microbiological and clinical response to tobramycin inhalation powder (TIP(tm)) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection

Journal of cystic fibrosis, 2011, Vol.10, p.S21-S21

2011

Volltextzugriff (PDF)

87 Effects of inhaled MP-376 (Aeroquin(tm), levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection

Journal of cystic fibrosis, 2011, Vol.10, p.S22-S22

2011

Volltextzugriff (PDF)

61 VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

Journal of cystic fibrosis, 2011, Vol.10, p.S16-S16

2011

Volltextzugriff (PDF)

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

Journal of cystic fibrosis, 2022-06, Vol.21, p.S1

2022

Volltextzugriff (PDF)

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

Journal of cystic fibrosis, 2022-07, Vol.21 (4), p.574-580

2022

Volltextzugriff (PDF)

P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations

Journal of cystic fibrosis, 2023-06, Vol.22, p.S93-S93

2023

Volltextzugriff (PDF)

Antipseudomonal treatment decisions during CF exacerbation management

Journal of cystic fibrosis, 2022-09, Vol.21 (5), p.753-758

2022

Volltextzugriff (PDF)

Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa ( Pa )

Journal of cystic fibrosis, 2010, Vol.9, p.S22-S22

2010

Volltextzugriff (PDF)

Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients

Journal of cystic fibrosis, 2010, Vol.9, p.S22-S22

2010

Volltextzugriff (PDF)

Pharmacokinetics (PK) of aerosol MP-376 (aeroquin; levofloxacin inhalation solution) in CF patients

Journal of cystic fibrosis, 2010, Vol.9, p.S23-S23

2010

Volltextzugriff (PDF)

Cystic fibrosis foundation position paper: Redefining the CF care model

Journal of cystic fibrosis, 2024-09

2024

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study

Adults with cystic fibrosis in Portugal: A first step towards improvement

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin

Corrigendum to “Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study” [J Cyst Fibros (2015) 632–638]

WS7.5 Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic Pseudomonas aeruginosa infection

WS13.2 Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects

WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis

WS23.6 Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study

321 Timing of inhaled tobramycin affects intravenous tobramycin trough levels

82 Microbiological and clinical response to tobramycin inhalation powder (TIP(tm)) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection

87 Effects of inhaled MP-376 (Aeroquin(tm), levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection

61 VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations

Antipseudomonal treatment decisions during CF exacerbation management

Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa ( Pa )

Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients

Pharmacokinetics (PK) of aerosol MP-376 (aeroquin; levofloxacin inhalation solution) in CF patients

Cystic fibrosis foundation position paper: Redefining the CF care model

Suchergebnisse filtern